THE BURDEN OF ROTAVIRUS GASTROENTERITIS, AS THE RATIONALE FOR ROUTINE VACCINATION

Rotavirus infection is the second after pneumococcal cause in the incidence of diseases and mortality in children under 5 years. That has defined the who’s recommendation for the introduction of vaccination against rotavirus infection in the vaccination schedules of all countries of the world. In our country that vaccination recommended for epidemic indications for introduction into the regional program. However, vaccination is carried out only in certain regions. One of the reasons for low uptake of this vaccine is the underestimation of the burden of disease.

The aim the study. To assess the significance of rotavirus gastroenteritis in the structure of acute gastroenteritis in children under 5 years receiving treatment in outpatient clinics, to study the genetic diversity of rotaviruses, to compare the costs associated with the treatment of acute rotavirus and non-rotavirus gastroenteritis.

Methods. Prospective, observational, epidemiological study. The inclusion of participants under the age of 5 years with the symptoms of acute gastroenteritis who meet the criteria of inclusion/exclusion. Examination, medical history, samples of faeces were carried out in the first day of treatment (day of inclusion in the study). Parents were given a questionnaire for 14 days. The severity of the disease was determined according to the scale of Vesicare, the disease dynamics was assessed by the answers of the questionnaire. Examination of feces samples was carried out centrally by PCR. Rotavirus positive samples were genotypically PCR and in case of detection of rare genotypes have been sequenced genomic RNA.

Results. The study included 501 baby — boys — 286 (57,1%), girls — 215 (42,9%). The average age was 22.6 ± 15.2 months. 50 children (10.0 per cent) mentioned various background pathology, the others were deemed healthy. Rotavirus was diagnosed in 151 patients 31.4% (95% CI: 26.9 percent - 35.3 percent), which accounted 66,52% (151 of 227) among all cases with confirmed etiology. Genotyping was prevalent G1P [8] to 34.5%, and G4P[8] — 39,2%. Clinical manifestations in rotavirus gastroenteritis was more severe, severe course observed in 65.5% of cases in the comparison group -at 30.4%. Significantly more often than in the comparison group (Р χ2 < 0,001) was observed vomiting (140
cases из151 — 93,3%, compared to 239 of 336 -71,1%) and elevated temperature (146 of 151 — 97,3% compared with 254 of 336 — 75,6%). The average temperature was 38,5 ± 0,6 OS in the comparison group — 38,0 ± 2,2 OS, remained 3,1 ± 1,4 and 2.5 ± 1.2 day, respectively. The frequency of episodes of diarrhoea in the first day of illness was 6.4 ± 2.7 times, in comparison with 5.2 ± 2.8, duration of diarrhea was 6.3 ± 3.2 days and 4.5 ± 2.6 days. The costs for parents of patients with acute rotavirus gastroenteritis was (M ± SD) 2873.4 ± 2276.4 rubles, against 2007.4 ± 2150.4 rubles in the comparison group (t = 3.965; p= < 0,001, as amended by Starlite for inequality of variances).

Conclusion. The introduction of routine vaccination of children in the first year of life will reduce by more than a third of the number of appeals to medical institutions about intestinal infections and partially prevent the costs associated with the treatment of this pathology.

1. Parashar UD, Hummelman EG, Bresee JS, Miller MA, Glass RI. Global illness and deaths caused by rotavirus disease in children. Emerg Infect Dis, 2003 May, 9(5): 565-72.

2. Tate JE, Burton AH, Boschi-Pinto C, Steele AD, Duque J, Parashar UD. 2008 estimate of worldwide rotavirus-associated mortality in children younger than 5 years before the introduction of universal rotavirus vaccination programmes: a systematic review and meta- analysis. Lancet Infect Dis, 2012 Jan, 12(1): 36-44. doi: 10.1016/S1473-3099(11)70295-X. Epub 2011 Oct 25.

3. Parashar UD, Burton A, Lanata C, Boschi-Pinto C, Shibuya K, Steele D, Birmingham M, Glass RI. Global Mortality Associated with Rotavirus Disease among Children in 2004. JID, 2009, 200(Suppl 1): 9-15.

4. Li L, Oza S, Hogan D, Chu Y, Perin J, Zhu J, Lawn JE, Cousens S, Mathers C, Blac RE. Global, regional, and national causes of under-5 mortality in 2000–15: an updated systematic analysis with implications for the Sustainable Development Goals. Lancet, 2016, 388: 3027– 35. http://dx.doi.org/10.1016/S0140-6736(16)31593-8.

5. Ogilvie I, Khoury H, Khoury АЕ, Goetghebeur MiM. Burden of rotavirus gastroenteritis in the pediatric population in central and eastern Europe Serotype distribution and burden of illness. Human Vaccines, 2011, May, 7(5): 523-533.

6. Soriano-Gabarro M, Mrukowicz J, Vesikari T, Verstraeten T. Burden of rotavirus disease in European Union countries. Pediatr Infect Dis J, 2006 Jan, 25(1 Suppl): 7-11.

7. Cortese MM, Parashar UD. Prevention of Rotavirus Gastroenteritis Infants and Children Recommendations of the Advisory Committee on Immunization Practices (ACIP). MMWR, 2009, February 6, 58(RR-2).

8. Rotavirus vaccines WHО position paper — January 2013. Weekly epidemiological record, 2013 Feb 1, 88 (5): 49–64.

9. О санитарно-эпидемиологического благополучия населения в Российской Федерации в 2015 году: Государственный доклад. М.: Федеральная служба по надзору в сфере защиты прав потребителей и благополучия человека, 2016. 200 с.

10. Подколзин А.Т., Петухов Д.Н., Веселова О.А. Публикация Референс центра по мониторингувозбудителей кишечных инфекций доступна на интернет странице центра Отчет РЦКИ: Данные о циркуляции ротавирусов группы А в РФ в зимний сезон 2011—2012 гг. www.epidoki.ru.

11. Инструкция по медицинскому применению лекарственного препарата РотаТек.

12. Global advisory Committee on Vaccine Safety, 11–12 December 2013. Update on intussusception following rotavirus vaccine administration. Weekly epidemiological record, 2014, 89(7): 53–60.

13. Zlamy M, Kofler S, Orth D, WЯrzner R, Heinz-Erian P, Streng A, Prelog M. The impact of Rotavirus mass vaccination on hospitalization rates, nosocomial Rotavirus gastroenteritis and secondary blood stream infections. BMC Infectious Diseases 2013, 13: 112. www.biomedcentral.com/1471-2334/13/112.

14. Aliabadi N, Tate JE, Haynes AK, Parashar UD. Sustained Decrease in Laboratory Detection of Rotavirus after Implementation of Routine Vaccination — United States, 2000–2014. Morbidity and Mortality Weekly Report, 2015 April 10, 64(13): 337-342.

15. Приказ Минздрава России № 125н от 21.03.2014 г. Об утверждении национального календаря профилактических прививок и календаря профилактических прививок по эпидемическим показаниям.

16. Рычкова О.А., Казакевич Н.В., Дубинина О.А., Шарухо Г.В., Курбатсая М.А., Иванова Г.Н., Подколзин А.Т., Суглобова С.Н., Сенникова Н.П., Лылова Т.П., Куличенко М.П. Профилактика ротавирусной инфекции: путь расширения региональной программы вакцинации Тюменской области. Фарматека, 2016, 11: 101-106.